A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC

The goal of this observational study is to evaluate the safety and efficacy of adebrelimab in the perioperative and advanced-stage treatment of small cell lung cancer （SCLC） under real-world conditions. The main questions it aims to answer are: 1. The safety of adebrelimab treatment in patients with advanced SCLC under real-world conditions, with a specific focus on the incidence of grade ≥3 immune-related adverse events. Safety monitoring begins when patients start receiving adebrelimab treatment and continues until 90 days after the last dose of adebrelimab. 2. Observe and evaluate the efficacy of adebrelimab in patients with small cell lung cancer under real-world conditions. This includes overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Additionally, the study seeks to further explore the impact of patient baseline characteristics, such as brain metastases or liver metastases, and biomarkers on prognosis.

NCT Number	NCT07434518
Lead Sponsor	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Collaborators: Shanghai Pulmonary Hospital, Shanghai, China, Shanghai Chest Hospital of Shanghai Jiao Tong University, Shanghai 10th People's Hospital, Shanghai Zhongshan Hospital, Huashan Hospital, RenJi Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine
Conditions	Small Cell Lung Cancer (SCLC)
Enrollment	500 participants
Start Date	2026-01-27
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-02-25